Print PDF
Axinn Successfully Represents Alvogen Before FTC
November 3, 2015

Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen’s approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan’s bid for Perrigo is valued at $25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC’s Mylan press release can be found here.

The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.